8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Feb 27, 2026·SEC
Prothena Corporation plc(PRTA)Earnings, Financials & Key Ratios
PRTA•NASDAQ
Price updated Jun 19, 2026
AboutProthena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.Show more
- Revenue$10M-92.8%
- EBITDA-$181M-17.7%
- Net Income-$244M-99.6%
- EPS (Diluted)-4.53-99.6%
- Gross Margin61.77%-38.2%
- EBITDA Margin-1867.6%-1542.6%
- Operating Margin-1905.82%-1566.6%
- Net Margin-2520.57%-2685.3%
- ROE-63.62%-172.6%
PRTA Key Insights
Prothena Corporation plc (PRTA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 62.6%
✗Weaknesses
- ✗Profits declining 17.0% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PRTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRTA Price & Volume
Prothena Corporation plc (PRTA) stock price & volume — 10-year historical chart
Loading chart...
PRTA Growth Metrics
Prothena Corporation plc (PRTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years19.68%
5 Years62.56%
3 Years-43.57%
TTM-57.99%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-37.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-35.58%
Return on Capital
10 Years-26.78%
5 Years-21.35%
3 Years-34.19%
Last Year-47.05%
PRTA Recent Earnings
Prothena Corporation plc (PRTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.52+267.7%
$0.31
Rev
$51M+6215.2%
$808,909
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$0.44+2.2%
$0.45
Rev
$21,000-98.4%
$1M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.67-11.7%
$0.60
Rev
$2M+262.2%
$666,670
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$1.86-67.6%
$1.11
Rev
$4M-33.4%
$7M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.52vs $0.31+267.7% | $51Mvs $808,909+6215.2% |
| Q1 2026 | Feb 19, 2026 | $0.44vs $0.45+2.2% | $21,000vs $1M-98.4% |
| Q4 2025 | Nov 6, 2025 | $0.67vs $0.60-11.7% | $2Mvs $666,670+262.2% |
| Q3 2025 | Aug 4, 2025 | $1.86vs $1.11-67.6% | $4Mvs $7M-33.4% |
Based on last 12 quarters of dataView full earnings history →
PRTA Peer Comparison
Prothena Corporation plc (PRTA) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 |
Compare PRTA vs Peers
Prothena Corporation plc (PRTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRTA Income Statement
Prothena Corporation plc (PRTA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 27.52M | 955K | 814K | 853K | 200.58M | 53.91M | 91.37M | 135.16M | 9.68M | 57.94M |
Revenue Growth % | 2508.44% | -96.53% | -14.76% | 4.79% | 23414.3% | -73.13% | 69.5% | 47.92% | -92.84% | -57.99% |
Cost of Goods Sold | 134.55M | 101.18M | 50.84M | 74.88M | 0 | 0 | 0 | 0 | 3.7M | 30.8M |
COGS % of Revenue | 488.92% | 10595.08% | 6245.21% | 8778.9% | - | - | - | - | 38.23% | - |
Gross Profit | -107.03M▲ 0% | -100.23M▲ 6.4% | -50.02M▲ 50.1% | -74.03M▼ 48.0% | 200.58M▲ 370.9% | 53.91M▼ 73.1% | 91.37M▲ 69.5% | 135.16M▲ 47.9% | 5.98M▼ 95.6% | 27.14M▲ 0% |
Gross Margin % | -388.92% | -10495.08% | -6145.21% | -8678.9% | 100% | 100% | 100% | 100% | 61.77% | 46.84% |
Gross Profit Growth % | 9.66% | 6.35% | 50.09% | -48% | 370.94% | -73.13% | 69.5% | 47.92% | -95.57% | - |
Operating Expenses | 182.77M | 143.66M | 35.67M | 38.7M | 128.6M | 185.46M | 282.41M | 289.72M | 190.54M | 153.42M |
OpEx % of Revenue | 664.17% | 15043.46% | 4382.68% | 4537.28% | 64.12% | 344.05% | 309.08% | 214.36% | 1967.6% | - |
Selling, General & Admin | 48.23M | 42.48M | 35.74M | 38.7M | 46.32M | 49.9M | 61.84M | 67.2M | 59.39M | 54.46M |
SG&A % of Revenue | 175.25% | 4448.38% | 4390.17% | 4537.28% | 23.09% | 92.57% | 67.68% | 49.72% | 613.3% | - |
Research & Development | 134.55M | 101.18M | 50.84M | 75.09M | 82.28M | 135.56M | 220.57M | 222.52M | 134.85M | 96.67M |
R&D % of Revenue | 488.92% | 10595.08% | 6245.21% | 8803.4% | 41.02% | 251.48% | 241.4% | 164.64% | 1392.52% | - |
Other Operating Expenses | -2.35M | 2.74M | -50.9M | -75.09M | 0 | 0 | 0 | 0 | -3.7M | -1.86M |
Operating Income | -155.25M▲ 0% | -158.85M▼ 2.3% | -85.7M▲ 46.1% | -112.73M▼ 31.5% | 71.97M▲ 163.8% | -131.56M▼ 282.8% | -191.04M▼ 45.2% | -154.56M▲ 19.1% | -184.56M▼ 19.4% | -126.28M▲ 0% |
Operating Margin % | -564.17% | -16634.03% | -10527.89% | -13216.18% | 35.88% | -244.05% | -209.08% | -114.36% | -1905.82% | -217.94% |
Operating Income Growth % | 2.68% | -2.32% | 46.05% | -31.55% | 163.84% | -282.78% | -45.21% | 19.09% | -19.41% | - |
EBITDA | -152.19M | -155.64M | -84.13M | -111.22M | 73.09M | -130.81M | -190.11M | -153.67M | -180.86M | -123.96M |
EBITDA Margin % | -553.03% | -16297.28% | -10335.75% | -13038.69% | 36.44% | -242.67% | -208.06% | -113.7% | -1867.6% | -213.95% |
EBITDA Growth % | 3.13% | -2.27% | 45.94% | -32.2% | 165.72% | -278.98% | -45.33% | 19.17% | -17.69% | 9.99% |
D&A (Non-Cash Add-back) | 3.07M | 3.22M | 1.56M | 1.51M | 1.11M | 744K | 928K | 893K | 3.7M | 2.31M |
EBIT | -153.91M | -152.42M | -85.76M | -112.73M | 71.97M | -131.56M | -191.04M | -154.56M | -200.83M | -83.97M |
Net Interest Income | -142K | 2.69M | 8.2M | 1.37M | 42K | 6.35M | 31.01M | 25.82M | 14.14M | 12.21M |
Interest Income | 3.55M | 6.39M | 8.2M | 1.37M | 42K | 6.35M | 31.01M | 25.82M | 14.14M | 12.21M |
Interest Expense | 3.69M | 3.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -2.35M | 2.74M | 8.4M | 1.87M | -54K | 5.95M | 30.56M | 25.63M | -16.27M | 20.28M |
Pretax Income | -157.6M▲ 0% | -156.12M▲ 0.9% | -77.3M▲ 50.5% | -110.86M▼ 43.4% | 71.92M▲ 164.9% | -125.61M▼ 274.6% | -160.48M▼ 27.8% | -128.93M▲ 19.7% | -200.83M▼ 55.8% | -105.99M▲ 0% |
Pretax Margin % | -572.71% | -16347.12% | -9496.07% | -12996.6% | 35.86% | -233.01% | -175.64% | -95.39% | -2073.82% | -182.93% |
Income Tax | -4.37M | -470K | 379K | 283K | 4.95M | -8.66M | -13.45M | -6.62M | 43.26M | 45.18M |
Effective Tax Rate % | 2.77% | 0.3% | -0.49% | -0.26% | 6.88% | 6.89% | 8.38% | 5.13% | -21.54% | -42.63% |
Net Income | -153.24M▲ 0% | -155.65M▼ 1.6% | -77.68M▲ 50.1% | -111.14M▼ 43.1% | 66.97M▲ 160.3% | -116.95M▼ 274.6% | -147.03M▼ 25.7% | -122.31M▲ 16.8% | -244.09M▼ 99.6% | -151.18M▲ 0% |
Net Margin % | -556.84% | -16297.91% | -9542.63% | -13029.78% | 33.39% | -216.95% | -160.92% | -90.49% | -2520.57% | -260.92% |
Net Income Growth % | 4.29% | -1.57% | 50.09% | -43.08% | 160.26% | -274.62% | -25.72% | 16.81% | -99.57% | -37.1% |
Net Income (Continuing) | -153.24M | -155.65M | -77.68M | -111.14M | 66.97M | -116.95M | -147.03M | -122.31M | -244.09M | -151.18M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4.07▲ 0% | -3.93▲ 3.4% | -1.95▲ 50.4% | -2.78▼ 42.6% | 1.38▲ 149.6% | -2.47▼ 279.0% | -2.76▼ 11.7% | -2.27▲ 17.8% | -4.53▼ 99.6% | -2.79▲ 0% |
EPS Growth % | 12.66% | 3.44% | 50.38% | -42.56% | 149.64% | -278.99% | -11.74% | 17.75% | -99.56% | -35.58% |
EPS (Basic) | -4.07 | -3.93 | -1.95 | -2.78 | 1.51 | -2.47 | -2.76 | -2.27 | -4.53 | - |
Diluted Shares Outstanding | 37.65M | 39.56M | 39.88M | 39.91M | 48.46M | 47.37M | 53.22M | 53.77M | 53.83M | 54.11M |
Basic Shares Outstanding | 37.65M | 39.56M | 39.88M | 39.91M | 44.23M | 47.37M | 53.22M | 53.77M | 53.83M | 53.71M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PRTA Balance Sheet
Prothena Corporation plc (PRTA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 426.33M | 431.39M | 378.38M | 299.28M | 584.81M | 719.1M | 639.28M | 485.41M | 315.19M | 339.2M |
Cash & Short-Term Investments | 417.62M | 427.66M | 375.72M | 295.38M | 579.09M | 710.41M | 618.83M | 471.39M | 307.53M | 329.46M |
Cash Only | 417.62M | 427.66M | 375.72M | 295.38M | 579.09M | 710.41M | 618.83M | 471.39M | 307.53M | 329.46M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 240K | 2K | 68K | 15K | 13K | 62K | 5.16M | 0 | 0 | 0 |
Days Sales Outstanding | 3.18 | 0.76 | 30.49 | 6.42 | 0.02 | 0.42 | 20.61 | - | - | - |
Inventory | -240K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 1.35M | 766K | 1.71M | 3.49M | 1.17M | 7.66M | 9.74M |
Total Non-Current Assets | 70M | 67.41M | 40.89M | 33.69M | 24.56M | 38.94M | 57.1M | 61.7M | 11.61M | 10.69M |
Property, Plant & Equipment | 54.99M | 52.84M | 27.15M | 20.36M | 14.13M | 8.01M | 16M | 13.79M | 10.27M | 9.35M |
Fixed Asset Turnover | 0.50x | 0.02x | 0.03x | 0.04x | 14.19x | 6.73x | 5.71x | 9.80x | 0.94x | 5.37x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 4.06M | 4.06M | 0 | 0 | 0 | 0 | 0 | 860K | 860K | 1.72M |
Other Non-Current Assets | 6.9M | 4.87M | 3.79M | 1.69M | 3.35M | 12.72M | 7.21M | 3.81M | 482K | 1.34M |
Total Assets | 496.33M▲ 0% | 498.8M▲ 0.5% | 419.27M▼ 15.9% | 332.98M▼ 20.6% | 609.37M▲ 83.0% | 758.03M▲ 24.4% | 696.38M▼ 8.1% | 547.11M▼ 21.4% | 326.8M▼ 40.3% | 349.89M▲ 0% |
Asset Turnover | 0.06x | 0.00x | 0.00x | 0.00x | 0.33x | 0.07x | 0.13x | 0.25x | 0.03x | 0.16x |
Asset Growth % | 7.9% | 0.5% | -15.94% | -20.58% | 83.01% | 24.4% | -8.13% | -21.44% | -40.27% | -148.57% |
Total Current Liabilities | 37.37M | 14.93M | 17.71M | 25.85M | 33.45M | 50.15M | 56.89M | 48.5M | 40.84M | 32.52M |
Accounts Payable | 13.63M | 1.47M | 1.24M | 4.12M | 3.69M | 9.27M | 25.39M | 7.77M | 5.88M | 4.3M |
Days Payables Outstanding | 36.98 | 5.3 | 8.92 | 20.07 | - | - | - | - | 579.25 | 97.4 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.89M | 2.89M |
Deferred Revenue (Current) | -857K | 110.24M | 0 | 0 | 7.66M | 11.44M | 0 | 8.85M | 2.66M | 9.39M |
Other Current Liabilities | 1.72M | 837K | 322K | 516K | 405K | 503K | 2.13M | 29.27M | 29.42M | 23.7M |
Current Ratio | 11.41x | 28.90x | 21.36x | 11.58x | 17.48x | 14.34x | 11.24x | 10.01x | 7.72x | 10.43x |
Quick Ratio | 11.41x | 28.90x | 21.36x | 11.58x | 17.48x | 14.34x | 11.24x | 10.01x | 7.72x | 10.43x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 51.77M | 160.87M | 128.63M | 123.12M | 109.87M | 85.85M | 78.13M | 11.68M | 5.49M | 4.76M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.49M | 4.76M |
Capital Lease Obligations | 51.52M | 49.9M | 17.84M | 12.33M | 6.39M | 0 | 10.72M | 8.23M | 5.49M | 18.62M |
Deferred Tax Liabilities | -254K | -49.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 254K | 110.97M | 553K | 553K | 553K | 553K | 0 | 0 | -5.49M | 0 |
Total Liabilities | 89.14M | 175.8M | 146.35M | 148.97M | 143.32M | 135.99M | 135.02M | 60.18M | 46.33M | 37.28M |
Total Debt | 52.25M | 51.55M | 22.94M | 17.84M | 12.33M | 6.47M | 11.84M | 10.84M | 13.86M | 7.65M |
Net Debt | -365.37M | -376.11M | -352.78M | -277.54M | -566.77M | -703.93M | -607M | -460.55M | -293.67M | -321.81M |
Debt / Equity | 0.13x | 0.16x | 0.08x | 0.10x | 0.03x | 0.01x | 0.02x | 0.02x | 0.05x | 0.02x |
Debt / EBITDA | - | - | - | - | 0.17x | - | - | - | - | -0.06x |
Net Debt / EBITDA | - | - | - | - | -7.75x | - | - | - | - | 2.60x |
Interest Coverage | -41.73x | -41.23x | - | - | - | - | - | - | - | - |
Total Equity | 407.19M▲ 0% | 323M▼ 20.7% | 272.92M▼ 15.5% | 184.01M▼ 32.6% | 466.04M▲ 153.3% | 622.04M▲ 33.5% | 561.37M▼ 9.8% | 486.93M▼ 13.3% | 280.47M▼ 42.4% | 312.62M▲ 0% |
Equity Growth % | 11.44% | -20.68% | -15.5% | -32.58% | 153.28% | 33.47% | -9.75% | -13.26% | -42.4% | -160.03% |
Book Value per Share | 10.81 | 8.16 | 6.84 | 4.61 | 9.62 | 13.13 | 10.55 | 9.06 | 5.21 | 5.78 |
Total Shareholders' Equity | 407.19M | 323M | 272.92M | 184.01M | 466.04M | 622.04M | 561.37M | 486.93M | 280.47M | 312.62M |
Common Stock | 385K | 399K | 399K | 399K | 466K | 521K | 537K | 538K | 538K | 530K |
Retained Earnings | -442.35M | -598M | -671.88M | -783.03M | -716.05M | -833M | -980.03M | -1.1B | -1.35B | -1.31B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -7.74M | -10.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRTA Cash Flow Statement
Prothena Corporation plc (PRTA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -131.18M | -28.28M | -52.97M | -80.36M | 92.61M | -108.82M | -133.91M | -150.05M | -163.58M | -81.34M |
Operating CF Margin % | -476.7% | -2960.84% | -6507.25% | -9421.1% | 46.17% | -201.88% | -146.55% | -111.02% | -1689.18% | - |
Operating CF Growth % | -11.87% | 78.45% | -87.33% | -51.72% | 215.23% | -217.51% | -23.05% | -12.06% | -9.02% | -174.83% |
Net Income | -153.24M | -155.65M | -77.68M | -111.14M | 66.97M | -116.95M | -147.03M | -122.31M | -244.09M | -151.18M |
Depreciation & Amortization | 3.07M | 3.22M | 6.82M | 1.51M | 1.11M | 744K | 928K | 893K | 895K | 856K |
Stock-Based Compensation | 26.76M | 27.01M | 23.59M | 22.01M | 24.66M | 31.32M | 40.91M | 45.96M | 37.64M | 33.61M |
Deferred Taxes | -2.2M | -1.59M | -1.25M | -1.69M | 4.57M | -11.13M | -15.69M | -9.35M | 43.24M | 44.91M |
Other Non-Cash Items | 1.59M | 4.28M | 0 | 5.46M | 5.69M | 6M | 7.5M | 2.69M | 2.91M | -2.24M |
Working Capital Changes | -7.16M | 94.45M | -4.45M | 3.48M | -10.4M | -18.8M | -20.53M | -67.94M | -4.17M | -7.3M |
Change in Receivables | -62K | 238K | 0 | 53K | 15K | 0 | -5.16M | 5.16M | 0 | 0 |
Change in Inventory | -396.2M | 9.6M | 0 | 0 | 0 | 0 | -8.9M | 0 | 0 | 0 |
Change in Payables | 147K | -25.63M | -78K | 7.73M | -492K | 11.87M | 22.86M | -18.3M | -15.78M | -18.91M |
Cash from Investing | -3.52M | -1.73M | -547K | -196K | -575K | -464K | -2.77M | -298K | -138K | -96K |
Capital Expenditures | -3.63M | -1.77M | -555K | -196K | -575K | -464K | -2.81M | -298K | -138K | -96K |
CapEx % of Revenue | 13.18% | 185.13% | 68.18% | 22.98% | 0.29% | 0.86% | 3.08% | 0.22% | 1.43% | 0.17% |
Acquisitions | 105K | 39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 105K | 39K | 8K | 0 | 0 | 0 | 37K | 0 | 0 | 0 |
Cash from Financing | 165.4M | 40.04M | 228K | 215K | 190.33M | 241.46M | 45.1M | 1.55M | -139K | -7.04M |
Debt Issued (Net) | -2.76M | -4.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 150.32M | 39.76M | 0 | 0 | 174.79M | 223.62M | 23.58M | -353K | -139K | -7.04M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -353K | 0 | -7.04M |
Other Financing | 17.84M | 4.69M | 228K | 215K | 15.54M | 17.84M | 21.52M | 1.91M | 0 | 0 |
Net Change in Cash | 30.7M▲ 0% | 10.04M▼ 67.3% | -53.29M▼ 630.8% | -80.34M▼ 50.8% | 282.36M▲ 451.4% | 132.17M▼ 53.2% | -91.58M▼ 169.3% | -148.79M▼ 62.5% | -163.86M▼ 10.1% | -88.47M▲ 0% |
Free Cash Flow | -134.81M▲ 0% | -30.04M▲ 77.7% | -53.52M▼ 78.2% | -80.56M▼ 50.5% | 92.03M▲ 214.2% | -109.28M▼ 218.7% | -136.72M▼ 25.1% | -150.35M▼ 10.0% | -163.72M▼ 8.9% | -81.44M▲ 0% |
FCF Margin % | -489.88% | -3145.97% | -6575.43% | -9444.08% | 45.88% | -202.74% | -149.63% | -111.24% | -1690.6% | -140.55% |
FCF Growth % | -0.67% | 77.71% | -78.15% | -50.51% | 214.24% | -218.75% | -25.1% | -9.97% | -8.89% | 37.64% |
FCF per Share | -3.58 | -0.76 | -1.34 | -2.02 | 1.90 | -2.31 | -2.57 | -2.80 | -3.04 | -1.51 |
FCF Conversion (FCF/Net Income) | 0.86x | 0.18x | 0.68x | 0.72x | 1.38x | 0.93x | 0.91x | 1.23x | 0.67x | 0.54x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 294K | 0 | 1.58M | 1.37M | 580K | 2.66M | 1.55M | 3.17M | 0 | 941K |
PRTA Key Ratios
Prothena Corporation plc (PRTA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -39.67% | -42.63% | -26.07% | -48.65% | 20.61% | -21.5% | -24.85% | -23.34% | -63.62% | -49.88% |
Return on Invested Capital (ROIC) | -325.18% | - | - | - | - | - | - | -439.41% | -2099.82% | 438.03% |
Gross Margin | -388.92% | -10495.08% | -6145.21% | -8678.9% | 100% | 100% | 100% | 100% | 61.77% | 46.84% |
Net Margin | -556.84% | -16297.91% | -9542.63% | -13029.78% | 33.39% | -216.95% | -160.92% | -90.49% | -2520.57% | -260.92% |
Debt / Equity | 0.13x | 0.16x | 0.08x | 0.10x | 0.03x | 0.01x | 0.02x | 0.02x | 0.05x | 0.02x |
Interest Coverage | -41.73x | -41.23x | - | - | - | - | - | - | - | - |
FCF Conversion | 0.86x | 0.18x | 0.68x | 0.72x | 1.38x | 0.93x | 0.91x | 1.23x | 0.67x | 0.54x |
Revenue Growth | 2508.44% | -96.53% | -14.76% | 4.79% | 23414.3% | -73.13% | 69.5% | 47.92% | -92.84% | -57.99% |
Related:PRTA Dividend History·PRTA Revenue History·PRTA Price History·PRTA P/E History·PRTA Financial Ratios·PRTA Institutional Holders
PRTA SEC Filings & Documents
Prothena Corporation plc (PRTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
PRTA Frequently Asked Questions
Prothena Corporation plc (PRTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Prothena Corporation plc (PRTA) reported $57.9M in revenue for fiscal year 2025. This represents a 4561% increase from $1.2M in 2010.
Prothena Corporation plc (PRTA) saw revenue decline by 92.8% over the past year.
Prothena Corporation plc (PRTA) reported a net loss of $151.2M for fiscal year 2025.
Dividend & Returns
Prothena Corporation plc (PRTA) has a return on equity (ROE) of -63.6%. Negative ROE indicates the company is unprofitable.
Prothena Corporation plc (PRTA) had negative free cash flow of $81.4M in fiscal year 2025, likely due to heavy capital investments.